Scientific and practical peer-reviewed journal for cardiologists and general practice physicians. Issued since 2005
ISSN 1819-6446 (Print) ISSN 2225-3653 (Online)
D.A. Kuzhel1,2*, G.V. Matyushin1, E.A. Savchenko1
1 Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky. Partizana Zheleznyaka ul. 1, Krasnoyarsk, 660022 Russia
2 Krasnoyarsk Territory Hospital N2. Karla Marxa ul. 43, Krasnoyarsk, 660097 Russia
Amiodarone is one of the basic antiarrhytmic drugs for atrial fibrillation treatment. However application of amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome can induce ventricular fibrillation. Amiodarone usage in these patients should be accompanied by readiness for performance of resuscitation. This is confirmed by clinical case presentation.
Key words: amiodarone, atrial fibrillation, Wolff-Parkinson-White syndrome, ventricular fibrillation.
Rational Pharmacother. Card. 2010;6(3):359-362
* Corresponding author: ofdkkb2@4mail.ru